Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: a population-based study.

Détails

Ressource 1Télécharger: 36474728_BIB_5D4A7E8E98EE.pdf (538.92 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_5D4A7E8E98EE
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: a population-based study.
Périodique
The Lancet regional health. Europe
Auteur⸱e⸱s
Zaballa M.E., Perez-Saez J., de Mestral C., Pullen N., Lamour J., Turelli P., Raclot C., Baysson H., Pennacchio F., Villers J., Duc J., Richard V., Dumont R., Semaani C., Loizeau A.J., Graindorge C., Lorthe E., Balavoine J.F., Pittet D., Schibler M., Vuilleumier N., Chappuis F., Kherad O., Azman A.S., Posfay-Barbe K.M., Kaiser L., Trono D., Stringhini S., Guessous I.
Collaborateur⸱rice⸱s
Specchio-COVID19 study group
Contributeur⸱rice⸱s
Arm-Vernez I., Azman A.S., Bachmann D., Bal A., Balavoine J.F., Balavoine M., Barbe R.P., Baysson H., Beigbeder L., Berthelot J., Bleich P., Boehm L., Bryand G., Chappuis F., Collombet P., Coudurier-Boeuf S., Courvoisier D., Cudet A., Davidovic V., de Mestral C., D'ippolito P., Dubos R., Dumont R., Eckerle I., El Merjani N., Flahault A., Francioli N., Frangville M., Graindorge C., Guessous I., Harnal S., Hurst S., Kaiser L., Kherad O., Lamour J., Lescuyer P., L'Huillier A.G., L'Huissier F., Loizeau A.J., Lorthe E., Martinez C., Ménard L., Metral-Boffod L., Moulin A., Nehme M., Noël N., Pennacchio F., Perez-Saez J., Pittet D., Posfay-Barbe K.M., Poulain G., Pugin C., Pullen N., Richard V., Rinaldi F., Rochat D., Sakvarelidze I., Samir K., Ramirez H.S., Satin E., Schaller P., Schibler M., Schrempft S., Semaani C., Stringhini S., Testini S., Trono D., Urrutia-Rivas D., Verolet C., Vetter P., Villers J., Violot G., Vuilleumier N., Wisniak A., Yerly S., Zaballa M.E.
ISSN
2666-7762 (Electronic)
ISSN-L
2666-7762
Statut éditorial
Publié
Date de publication
01/2023
Peer-reviewed
Oui
Volume
24
Pages
100547
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
More than two years into the COVID-19 pandemic, most of the population has developed anti-SARS-CoV-2 antibodies from infection and/or vaccination. However, public health decision-making is hindered by the lack of up-to-date and precise characterization of the immune landscape in the population. Here, we estimated anti-SARS-CoV-2 antibodies seroprevalence and cross-variant neutralization capacity after Omicron became dominant in Geneva, Switzerland.
We conducted a population-based serosurvey between April 29 and June 9, 2022, recruiting children and adults of all ages from age-stratified random samples of the general population of Geneva, Switzerland. We tested for anti-SARS-CoV-2 antibodies using commercial immunoassays targeting either the spike (S) or nucleocapsid (N) protein, and for antibody neutralization capacity against different SARS-CoV-2 variants using a cell-free Spike trimer-ACE2 binding-based surrogate neutralization assay. We estimated seroprevalence and neutralization capacity using a Bayesian modeling framework accounting for the demographics, vaccination, and infection statuses of the Geneva population.
Among the 2521 individuals included in the analysis, the estimated total antibodies seroprevalence was 93.8% (95% CrI 93.1-94.5), including 72.4% (70.0-74.7) for infection-induced antibodies. Estimates of neutralizing antibodies in a representative subsample (N = 1160) ranged from 79.5% (77.1-81.8) against the Alpha variant to 46.7% (43.0-50.4) against the Omicron BA.4/BA.5 subvariants. Despite having high seroprevalence of infection-induced antibodies (76.7% [69.7-83.0] for ages 0-5 years, 90.5% [86.5-94.1] for ages 6-11 years), children aged <12 years had substantially lower neutralizing activity than older participants, particularly against Omicron subvariants. Overall, vaccination was associated with higher neutralizing activity against pre-Omicron variants. Vaccine booster alongside recent infection was associated with higher neutralizing activity against Omicron subvariants.
While most of the Geneva population has developed anti-SARS-CoV-2 antibodies through vaccination and/or infection, less than half has neutralizing activity against the currently circulating Omicron BA.5 subvariant. Hybrid immunity obtained through booster vaccination and infection confers the greatest neutralization capacity, including against Omicron.
General Directorate of Health in Geneva canton, Private Foundation of the Geneva University Hospitals, European Commission ("CoVICIS" grant), and a private foundation advised by CARIGEST SA.
Mots-clé
Anti-SARS-CoV-2 antibodies, Neutralizing antibodies, Omicron, Seroprevalence, Switzerland, Variants of concern
Pubmed
Web of science
Open Access
Oui
Création de la notice
12/12/2022 9:43
Dernière modification de la notice
23/01/2024 8:26
Données d'usage